Zahlreiche Biologika haben in Off-Label-Anwendung bei schwerer chronischer nicht-infektiöser Uveitis Wirksamkeit gezeigt, vor allem TNF-α-Inhibitoren und Interferon alpha.
Bisher beschränkt sich der Einsatz meist auf therapierefraktäre Fälle.
Als First-Line-Therapie können Biologika bei schweren Formen von z. B. okulärem Mb. Behçet erwogen werden.
Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.
1 Becker M.D., Adamus G., Davey M.P., Rosenbaum J.T.: The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm 2000; 8: 93–100
2 Suhler E.B., Smith J.R., Giles T.R. et al.: Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch. Ophthalmol 2009; 127 (6): 819–22
3 Niccoli L., Nannini C., Benucci M. et al.: Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46 (7): 1161–64
4 Yamada Y., Sugita S., Tanaka H. et al.: Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 2010 Mar; 94 (3): 284–8
5 Tynjala P., Lindahl P., Honkanen V. et al.: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66 (4): 548–50
6 Rudwaleit M., Rødevand E., Holck P. et al.: Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active akylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009; 68 (5): 696–701
7 Simonini G., Taddio A., Cattalini M. et al.: Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011; 63 (4): 612–18
8 Levy-Clarke G., Jabs D.A., Read R.W., Van Gelder R.N.: Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology 2014; 121: 785–96
9 Gueudry J., Wechsler B., Terrada C. et al.: Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol Dec 2008; 146 (6): 837–44
10 Hatemi G., Silman A., Bang D. et al.: Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis Oct 2009; 68 (10): 1528–34
11 Gul A., Tugal-Tutkun I., Dinarello C.A. et al.: IL-1b-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 2012; 71 (4): 563–66
12 Muselier A., Bielefeld P., Bidot S. et al.: Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm Oct 2011; 19 (5): 382–3
13 Hirano T., Ohguro N., Hohki S. et al.: A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol Apr 2012; 22 (2): 298–302
14 Hueber W., Patel D.D., Dryja T. et al.: Effects of AIN457, a fully human antibody to IL-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2 (52)
15 Dick A.D., Tugal-Tutkun I., Foster S. et al.: Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology 2013; 120 (4)
16 Miserocchi E., Pontikaki I., Modorati G. et al.: Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011; 11 (1): 35–9
17 Heiligenhaus A., Miserocchi E., Heinz C. et al.: Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011; 50 (8): 1390–4
18 Davatchi F., Shams H., Rezaipoor M. et al.: Rituximab in intractable ocular lesions of Behcet’s disease; randomized singleblind control study (pilot study). Int J Rheum Dis 2010; 13 (3): 246–52
19 Pelegrin L., Jakob E., Schmidt-Bacher A. et al.: Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement. J Rheumatol 2014; 41 (1): 84–90
20 Zulian F., Balzarin M., Falcini F. et al.: Abatacept for severe Anti-TNF a refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010; 62 (6): 821–25
21 Kenawy N., Cleary G., Mewar D. et al.: Abatacept: a potential therapy in refractory cases of JIA-associated uveitis. Graefes Arch. Clin Exp Ophthalmol 2011; 249 (2): 297–300
22 Murphy C.C., Ayliffe W.H., Booth A. et al.: Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352–56
23 Chauhan S., Kamal A., Thompson R.N. et al.: Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 2009; 93: 984–85
